Multiple Myeloma in Relapse Clinical Trial
Official title:
A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Status | Not yet recruiting |
Enrollment | 39 |
Est. completion date | December 31, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Have a diagnosis of MM based on standard criteria as follows, both criteria a and b must be met: c. Clonal BM plasma cells = 10% or biopsy-proven bony or extramedullary plasmacytoma d. Any or more of the following myeloma defining events: i. Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: 1. Hypercalcemia: serum calcium >2.75 mmol/L (>11 mg/dL) or >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal 2. Renal insufficiency: creatinine clearance < 40mL/min or serum creatinine > 177 mmol/L (> 2mg/dL) 3. Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL 4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT ii. Clonal BM plasma cell percentage > 60% iii. Involved: uninvolved SFLC ratio >100 (involved FLC level must be >100 mg/L) iv. > 1 focal lesion on MRI studies (at least 5 mm in size) 2. Show the t(11;14), confirmed by FISH or cytogenetic analysis , to be performed within 28 days prior to baseline. If performed more than 28 days prior, it should be repeated at the investigator's discretion 3. Absolute neutrophil count = 1.5 x 10/L 4. Platelet count = 75 x 109/L 5. Hemoglobin = 8.0 g/dL within 21 days prior to enrollment. 6. Calculated or measured creatinine clearance (CrCl) of = 30 mL/minute as calculated by Cockcroft-Gault method 7. Total bilirubin levels = 2.0 mg/dL (normal levels) 8. AST (SGOT) and ALT (SGPT) = 2 x ULN 9. Serum potassium within the normal range 10. Female of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting and must either commit to continued abstinence from heterosexual intercourse or use acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, and at least 28 days before she starts taking treatment drugs. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Contraception measures should be continued for 3 months following the treatment completion. - A FCBP (female of childbearing potential) is a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months 11. Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 2 12. Participant must have received at least 3 lines of prior treatment for MM, including regimens that contained a proteasome inhibitor, lenalidomide, and glucocorticosteroids 13. Participant currently has documented progressive MM per IMWG criteria 14. Subject must be = 18 years of age 15. Subject must voluntarily sign and date an informed consent Exclusion Criteria: 1. Participant has a history of intolerability to any of the study drugs 2. Participant has any of the following conditions: amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), known human immunodeficiency viral (HIV) infection, active hepatitis B or C infection based on blood screen tests, significant cardiovascular disease, including uncontrolled angina, severe or uncontrolled arrhythmia, recent myocardial infarction within 6 months of screening, or congestive heart failure New York Heart Association (NYHA) Class greater than or equal to 3, major surgery within 4 weeks prior to screening, acute infections requiring parenteral therapy (antibiotic, antifungal, or antiviral) within 14 days prior to screening, peripheral neuropathy greater than or equal to Grade 3 or greater than or equal to Grade 2 with pain within 2 weeks prior to screening, uncontrolled diabetes or uncontrolled hypertension within 14 days prior to screening, any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study 3. Participant has a history of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions: previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study 4. If participant had prior allogeneic stem cell transplant (SCT), participant has evidence of ongoing graft-versus-host disease (GvHD) 5. Participants that are pregnant or breast feeding 6. Participants with hypersensitivity to any study medications and/or their excipients 7. Treatment with an anti-CD38 antibody (daratumumab or isatuximab) within the last six months 8. Treatment with an anti-CD38 antibody (daratumumab or isatuximab), alone or in combination, without achieving a best response of at least a MR 9. Treatment with venetoclax 10. Participants that are refractory to anti-CD38 antibody treatment [i.e. disease progression (i.e., PD, per IMWG criteria) while receiving a CD38 MoAb or within 60 days of treatment (PD after 60 days after CD38 MoAb treatment is allowed)] 11. Treatment with any of the following within 7 days prior to the first dose of study drug: 1. Steroid therapy for anti-neoplastic intent 2. Moderate or strong cytochrome P450 3A (CYP3A) inhibitors or inducers 12. Administration or consumption of any of the following within 3 days prior to the first dose of study drug: d. Grapefruit or grapefruit products e. Seville oranges (including marmalade containing Seville oranges) f. Star fruit 13. Additional prior and concomitant therapy excluded and cautionary medications: c. Excluded: i. Anticancer therapies including chemotherapy, radiotherapy, or other investigational therapy, including targeted small molecule agents: Excluded 5 half-lives prior to first dose and throughout venetoclax administration ii. Biologic agents (e.g., monoclonal antibodies) for anti-neoplastic intent: Excluded 28 days prior to first dose and throughout venetoclax administration d. Cautionary during the study: i. Strong and Moderate CYP3A inhibitors: Exclude during ramp-up phase and consider alternative medications. If subject requires use of these medications at the cohort designated dose, use with caution and reduce the venetoclax dose by 50% for moderate inhibitors and at least 75% for strong inhibitors during co-administration. After discontinuation of CYP3A inhibitor, wait for 2 to 3 days before venetoclax dose is increased back to the initial maintenance/target dose. ii. Strong and Moderate CYP3A inducers: Exclude during ramp-up phase and consider alternative medications. If subject requires use of these medications at the cohort designated dose, use with caution and contact AbbVie medical monitor for guidance. iii. Additional: Warfarin, P-gp substrates, BCRP substrates, OATP1B1/1B3 substrates, P-gp inhibitors, BCRP inhibitors |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Oncotherapeutics |
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Mace S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum In: Lancet. 2019 Dec 7;394(10214):2072. — View Citation
Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, Plesner T, Moreau P, Gibbs SD, Coppola S, Yang X, Al Masud A, Ross JA, Bueno O, Kaufman JL. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13. — View Citation
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1. — View Citation
Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8. — View Citation
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Mace S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. — View Citation
Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR. Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18. No abstract available. — View Citation
Regidor B, Goldwater MS, Wang J, Bujarski S, Swift R, Eades B, Emamy-Sadr M, Eshagian S, Schwartz G, Spektor TM, Berenson JR. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study. Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14. — View Citation
Smith ML, Newland AC. Treatment of myeloma. QJM. 1999 Jan;92(1):11-4. doi: 10.1093/qjmed/92.1.11. — View Citation
Touzeau C, Le Gouill S, Mahe B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biomarker (sBCMA) screening for all patients | In this study, we will assess the serum levels of a new serum biomarker for MM, BCMA. It is a tumor necrosis factor receptor family member that is expressed on the surface of normal and malignant B-cells, including MM cells. Serum (s)BCMA levels have been shown to be elevated among MM patients with progressive disease and low among those responding to treatment. In addition to correlating with clinical status, baseline sBCMA levels have been shown to predict PFS and OS. Changes in its levels also mirror those that occur in M protein levels. | [Time Frame: 54 months] | |
Primary | Incidence of Treatment-Emergent Adverse Events [Safety] | Safety will be measured by counting the occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 criteria | [Time Frame: 54 months] | |
Primary | Overall response rate (ORR) as a measure of efficacy | To assess the overall response rate (ORR = CR + VGPR + PR) | [Time Frame: 54 months] | |
Primary | Clinical benefit rate (CBR) as a measure of efficacy | (CBR = CR + VGPR + PR + MR) | [Time Frame: 54 months] | |
Secondary | Assessment of the time to progression as a measure of efficacy (TTP) | Time to progression, defined as the time (in months) from the initiation of therapy to progressive disease.Time to progression, defined as the time (in months) from the initiation of therapy to progressive disease. | [Time Frame: 54 months] | |
Secondary | Progression Free Survival (PFS) | Progression-free survival will be measured in months as the time from initiation of therapy to progressive disease or death from any cause, whichever occurs first | [Time Frame: 54 months] | |
Secondary | Time to first response (TTFR) | Time to first response (TTFR), defined as the time from the initiation of therapy to the first evidence of confirmed clinical benefit defined as > MR including patients who achieved a CR, VGPR, PR, or MR | [Time Frame: 54 months] | |
Secondary | Duration of response (DOR) | Duration of response, defined as the time (in months) from the first response to progressive disease | [Time Frame: 54 months] | |
Secondary | Overall survival (OS) | Overall survival, defined as the time (in months) from initiation of therapy to death from any cause or last follow-up visit | [Time Frame: 54 months] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01435720 -
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04094961 -
Ixazomib + Pomalidomide + Dexamethasone In MM
|
Phase 1/Phase 2 | |
Recruiting |
NCT06068400 -
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
|
N/A | |
Recruiting |
NCT03601624 -
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
|
Phase 2 | |
Recruiting |
NCT05020444 -
TriPRIL CAR T Cells in Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT03706547 -
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
|
Phase 1 | |
Active, not recruiting |
NCT02970747 -
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
|
||
Not yet recruiting |
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 | |
Completed |
NCT01965353 -
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
Not yet recruiting |
NCT05581875 -
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
|
Phase 1/Phase 2 | |
Terminated |
NCT03687125 -
Tinostamustine Conditioning and Autologous Stem Cell
|
Phase 1/Phase 2 | |
Recruiting |
NCT06282978 -
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
|
Phase 2 | |
Recruiting |
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 | |
Active, not recruiting |
NCT03030261 -
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04925193 -
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
Recruiting |
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 | |
Terminated |
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 | |
Completed |
NCT03136653 -
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
|
Phase 1/Phase 2 |